Utility of 10 immunohistochemical markers including novel markers (desmocollin-3, glypican 3, S100A2, S100A7, and Sox-2) for differential diagnosis of squamous cell carcinoma from adenocarcinoma of the lung

Journal of Thoracic Oncology

Volumn 6, Issue 7, 2011, Pages 1190-1199

  Tsuta, Koji ^a   Tanabe, Yuko ^a   Yoshida, Akihiko ^a   Takahashi, Fumiaki ^a   Maeshima, Akiko M ^a   Asamura, Hisao ^b   Tsuda, Hitoshi ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b KITASATO UNIVERSITY   (Japan)

Author keywords

Cytokeratin 5 6; Desmocollin 3; Lung; Sox2; Squamous cell carcinoma

Indexed keywords

CYTOKERATIN; CYTOKERATIN 5; CYTOKERATIN 6; DESMOCOLLIN 3; GLYPICAN 3; HIGH MOLECULAR WEIGHT CYTOKERATIN; PROTEIN P63; PROTEIN S100A2; PSORIASIN; THROMBOMODULIN; THYROID TRANSCRIPTION FACTOR 1; TRANSCRIPTION FACTOR SOX2; TUMOR MARKER; UNCLASSIFIED DRUG;

ARTICLE; CANCER DIAGNOSIS; CANCER GRADING; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIFFERENTIAL DIAGNOSIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LUNG ADENOCARCINOMA; LUNG SQUAMOUS CELL CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; TUMOR DIFFERENTIATION;

EID: 79959893168     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e318219ac78     Document Type: Article

References (40)

1. Travis W. Pathology and Genetics of the Lung Tumors. Lyon, France: IARC Press, 2004.
2. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy- naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26:3543-3551.
3. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small cell lung cancer. N Engl J Med 2006;355: 2542-2550. (Pubitemid 44917502)
4. Rossi G, Marchioni A, Milani M, et al. TTF-1, cytokeratin 7, 34betaE12, and CD56/NCAM immunostaining in the subclassification of large cell carcinomas of the lung. Am J Clin Pathol 2004;122:884-893. (Pubitemid 39577356)
5. Loo PS, Thomas SC, Nicolson MC, et al. Subtyping of undifferentiated non-small cell carcinomas in bronchial biopsy specimens. J Thorac Oncol 2010;5:442-447.
6. Rossi G, Pelosi G, Graziano P, et al. A reevaluation of the clinical significance of histological subtyping of non-small-cell lung carcinoma: Diagnostic algorithms in the era of personalized treatments. Int J Surg Pathol 2009;17:206-218.
7. Nicholson AG, Gonzalez D, Shah P, et al. Refining the diagnosis and EGFR status of non-small cell lung carcinoma in biopsy and cytologic material, using a panel of mucin staining, TTF-1, cytokeratin 5/6, and P63, and EGFR mutation analysis. J Thorac Oncol 2010;5:436-441.
8. Terry J, Leung S, Laskin J, et al. Optimal immunohistochemical markers for distinguishing lung adenocarcinomas from squamous cell carcinomas in small tumor samples. Am J Surg Pathol 2010;34:1805-1811.
9. Mukhopadhyay S, Katzenstein AL. Subclassification of non-small cell lung carcinomas lacking morphologic differentiation on biopsy specimens: Utility of an immunohistochemical panel containing TTF-1, napsin A, p63, and CK5/6. Am J Surg Pathol 2011;35:15-25.
10. Kaufmann O, Dietel M. Thyroid transcription factor-1 is the superior immunohistochemical marker for pulmonary adenocarcinomas and large cell carcinomas compared to surfactant proteins A and B. Histopathology 2000;36:8-16. (Pubitemid 30055417)
11. Kaufmann O, Fietze E, Mengs J, et al. Value of p63 and cytokeratin 5/6 as immunohistochemical markers for the differential diagnosis of poorly differentiated and undifferentiated carcinomas. Am J Clin Pathol 2001; 116:823-830. (Pubitemid 33108152)
12. Pelosi G, Fraggetta F, Pasini F, et al. Immunoreactivity for thyroid transcription factor-1 in stage I non-small cell carcinomas of the lung. Am J Surg Pathol 2001;25:363-372. (Pubitemid 32175139)
13. Tan D, Li Q, Deeb G, et al. Thyroid transcription factor-1 expression prevalence and its clinical implications in non-small cell lung cancer: A high-throughput tissue microarray and immunohistochemistry study. Hum Pathol 2003;34:597-604. (Pubitemid 36750372)
14. Kargi A, Gurel D, Tuna B. The diagnostic value of TTF-1, CK 5/6, and p63 immunostaining in classification of lung carcinomas. Appl Immunohistochem Mol Morphol 2007;15:415-420. (Pubitemid 350307847)
15. Monica V, Ceppi P, Righi L, et al. Desmocollin-3: A new marker of squamous differentiation in undifferentiated large-cell carcinoma of the lung. Mod Pathol 2009;22:709-717.
16. Matoso A, Singh K, Jacob R, et al. Comparison of thyroid transcription factor-1 expression by monoclonal antibodies in pulmonary and nonpulmonary primary tumors. Appl Immunohistochem Mol Morphol 2010;18: 142-149.
17. Conde E, Angulo B, Redondo P, et al. The use of P63 immunohistochemistry for the identification of squamous cell carcinoma of the lung. PLoS One 2010;5:e12209.
18. Reis-Filho JS, Simpson PT, Martins A, et al. Distribution of p63, cytokeratins 5/6 and cytokeratin 14 in 51 normal and 400 neoplastic human tissue samples using TARP-4 multi-tumor tissue microarray. Virchows Arch 2003;443:122-132. (Pubitemid 37056135)
19. Au NH, Gown AM, Cheang M, et al. P63 expression in lung carcinoma: A tissue microarray study of 408 cases. Appl Immunohistochem Mol Morphol 2004;12:240-247.
20. Sheikh HA, Fuhrer K, Cieply K, et al. p63 expression in assessment of bronchioloalveolar proliferations of the lung. Mod Pathol 2004;17: 1134-1140. (Pubitemid 39128240)
21. Ang DC, Ghaffar H, Zakowski MF, et al. Expression of squamous markers in lung adenocarcinoma: Clinicopathologic and molecular correlates, and implications for differentiation from squamous cell carcinoma. Mod Pathol 2010;23:397A.
22. Chu PG, Weiss LM. Keratin expression in human tissues and neoplasms. Histopathology 2002;40:403-439. (Pubitemid 34535443)
23. Pan CC, Chen PC, Chou TY, et al. Expression of calretinin and other mesothelioma-related markers in thymic carcinoma and thymoma. Hum Pathol 2003;34:1155-1162. (Pubitemid 37467001)
24. Camilo R, Capelozzi VL, Siqueira SA, et al. Expression of p63, keratin 5/6, keratin 7, and surfactant-A in non-small cell lung carcinomas. Hum Pathol 2006;37:542-546.
25. Aviel-Ronen S, Lau SK, Pintilie M, et al. Glypican-3 is overexpressed in lung squamous cell carcinoma, but not in adenocarcinoma. Mod Pathol 2008;21:817-825. (Pubitemid 351896655)
26. Smith SL, Gugger M, Hoban P, et al. S100A2 is strongly expressed in airway basal cells, preneoplastic bronchial lesions and primary nonsmall cell lung carcinomas. Br J Cancer 2004;18:91:1515-1524. (Pubitemid 39486357)
27. Zhang H, Zhao Q, Chen Y, et al. Selective expression of S100A7 in lung squamous cell carcinomas and large cell carcinomas but not in adenocarcinomas and small cell carcinomas. Thorax 2008;63:352-359. (Pubitemid 351497949)
28. Sholl LM, Long KB, Hornick JL. Sox2 expression in pulmonary nonsmall cell and neuroendocrine carcinomas. Appl Immunohistochem Mol Morphol 2010;18:55-61.
29. Jerome Marson V, Mazieres J, Groussard O, et al. Expression of TTF-1 and cytokeratins in primary and secondary epithelial lung tumours: Correlation with histological type and grade. Histopathology 2004;45: 125-134. (Pubitemid 39120408)
30. Blobel GA, Moll R, Franke WW, et al. Cytokeratins in normal lung and lung carcinomas. I. Adenocarcinomas, squamous cell carcinomas and cultured cell lines. Virchows Arch B Cell Pathol Incl Mol Pathol 1984;45:407-429. (Pubitemid 14139638)
31. Bass AJ, Watanabe H, Mermel CH, et al. SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet 2009;41:1238-1242.
32. Bjorkqvist AM, Husgafvel-Pursiainen K, Anttila S, et al. DNA gains in 3q occur frequently in squamous cell carcinoma of the lung, but not in adenocarcinoma. Genes Chromosomes Cancer 1998;22:79-82. (Pubitemid 28217810)
33. Sholl LM, Barletta JA, Yeap BY, et al. Sox2 protein expression is an independent poor prognostic indicator in stage I lung adenocarcinoma. Am J Surg Pathol 2010;34:1193-1198.
34. Boelens MC, van den Berg A, Vogelzang I, et al. Differential expression and distribution of epithelial adhesion molecules in non-small cell lung cancer and normal bronchus. J Clin Pathol 2007;60:608-614. (Pubitemid 46975213)
35. Angulo B, Suarez-Gauthier A, Lopez-Rios F, et al. Expression signatures in lung cancer reveal a profile for EGFR-mutant tumours and identify selective PIK3CA overexpression by gene amplification. J Pathol 2008;214:347-356. (Pubitemid 351212390)
36. Miettinen M, Sarlomo-Rikala M. Expression of calretinin, thrombomodulin, keratin 5, and mesothelin in lung carcinomas of different types: An immunohistochemical analysis of 596 tumors in comparison with epithelioid mesotheliomas of the pleura. Am J Surg Pathol 2003;27: 150-158. (Pubitemid 36152223)
37. Wu M, Wang B, Gil J, et al. p63 and TTF-1 immunostaining: A useful marker panel for distinguishing small cell carcinoma of lung from poorly differentiated squamous cell carcinoma of lung. Am J Clin Pathol 2003;119:696-702. (Pubitemid 37051496)
38. Zhang H, Liu J, Cagle PT, et al. Distinction of pulmonary small cell carcinoma from poorly differentiated squamous cell carcinoma: An immunohistochemical approach. Mod Pathol 2005;18:111-118. (Pubitemid 40128103)
39. Lyda MH, Weiss LM. Immunoreactivity for epithelial and neuroendocrine antibodies are useful in the differential diagnosis of lung carcinomas. Hum Pathol 2000;31:980-987.
40. Perner S, Wagner PL, Soltermann A, et al. TTF1 expression in nonsmall cell lung carcinoma: Association with TTF1 gene amplification and improved survival. J Pathol 2009;217:65-72.